A movement to promote and conduct research on the treatment and prevention of drug-resistant tuberculosis, with a commitment to address the substantial existing gaps in our knowledge and to help provide access to an effective cure and prophylaxis of drug-resistant tuberculosis throughout the world.

more

Nearly nine million people will develop tuberculosis (TB) in the world this year; at least 500,000 of these cases will have multidrug-resistant tuberculosis (MDR-TB). Some will receive treatment. However, we know little about the best ways of treating drug-resistant TB (DR-TB) and preventing tuberculosis in people who come in contact with DR-TB patients. Lacking a strong scientific basis in prescribing treatment regimens, existing TB treatments are often ineffective. TB control efforts require new evidence-based knowledge about optimal treatment regimens, prophylaxis, and, possibly, regimens involving new TB drugs, in order to address the growing health threats of MDR-TB and extensively drug-resistant (XDR) TB.

Sign up for our monthly newsletter and review of recent literature!

To view our most recent newsletter click here!

ribs_resized

Drug to Treat MDR-TB to be
Made Available Across India

 

New Delhi, Apr 11: The Centre has decided to expand the availability of Bedaquiline, a drug used for treatment of drug-resistant tuberculosis, across the country.

Union Health Minister J P Nadda said that under the revised National TB Control Programme (RNTCP) in India, the drug is currently available in five cities – Ahmedabad, Delhi, Chennai, Mumbai and Guwahati.

“Based on the limited use of the drug in these five states and cities, it has been decided to expand the availability in rest of the country. Country-wide training is being carried out to build capacity of other states, and the states are also being prepared to monitor the treatment of patients with Bedaquiline containing regimen,” Nadda said.

Read the full article here.

Recent News and Announcements

Webinar Series: April 20th TB-CHAMP Trial

Mark your calendar for Thursday, April 20th from 08:30 to 09:30 EST (14:30-15:30 CEST, SAST) for a presentation by Dr. Anneke Hesseling, MBChB, MSc, PhD, on the TB-CHAMP Trial.  The TB-CHAMP Trial is a phase III cluster randomized, double blind, placebo-controlled, superiority multicenter trial that aims to evaluate the efficacy of levofloxacin versus placebo as preventative therapy against MDR-TB in […]

Programmatic Management of Drug-Resistant Tuberculosis: An Updated Research Agenda

There are numerous challenges in delivering appropriate treatment for multidrug-resistant tuberculosis (MDR-TB) and the evidence base to guide those practices remains limited. This article presents the third updated Research Agenda for the programmatic management of drug-resistant TB (PMDT), assembled through a literature review and survey. Conclusions state that there is continuity around the priorities for research […]

WORLD TB DAY 2017

On March 24 we commemorate World TB Day in recognition of the day in 1882 when Dr. Robert Koch announced his discovery of M. tuberculosis. While progress has been made, TB remains one of the top 10 causes of death worldwide 135 years after Dr. Koch’s discovery; in 2015, an estimated 1 million children became ill with […]

endTB Partnership Launches Clinical Trial to Target Toughest Strains of TB

Médecins Sans Frontières (MSF), Partners In Health (PIH) and other leading medical organizations have launched a major clinical trial which seeks to revolutionize treatment for the toughest strains of tuberculosis (TB). The first patient started treatment in Georgia earlier this month. This phase III clinical trial is part of a UNITAID-funded transformative project called endTB, […]

Advocates call on Sequella to provide open access to sutezolid data

In an open letter sent to Sequella on 21 February 2017, TB advocates called attention to the recent agreement between Johns Hopkins University and the Medicines Patent Pool regarding the rights to develop sutezolid in combination for TB, and urged Sequella to provide open access to all existing clinical data for sutezolid to facilitate and accelerate its further […]

Event Calendar

Social Media